INSTITUTIONAL BIOSAFETY COMMITTEE
IBC MEETING MINUTES
November 13, 2025

MEMBERS PRESENT: JoEllyn McMillan - Chair, Pete Iwen – Vice Chair, Jim Kee, Jenna McKenzie, Jim Talmadge, Mimi McCann, Vinai Thomas, Eric Bradley, Noel Johnson, and Paul Denton

NON-VOTING ALTERNATE MEMBERS PRESENT: Mackenzie Conrin, Jared Evans, and Makayla Walker, Ryan Duden, Sue Logsdon

ADMINISTRATIVE STAFF PRESENT: Jackie Hollinger

GUESTS PRESENT: Stephen Asante-Adde

Dr. McMillan opened the meeting at 2:35pm.

A. Review and Acceptance of IBC Minutes

The IBC voted (10 in favor, 0 against, 0 abstention) to accept October 9, 2025 minutes.

B. Information, Education and Policy Items

- IBC agreed to remove protocols from “problem child” 1-year review list after they have completed the continuing review submission requirements.

C. Special Notification/Review

none

D. Incident and Event Reports Special Notification and/or Review Approved

none

E. IBC Initial Research Proposals and/or Previously Tabled

1) **IBC#:** 25-10-023-ABL1
PI: Fernandez-Pena, Carlos
Title: Neurobiology of anxiety and anxiety disorders
Biohazardous Agents: adeno-associated virus
Applicable NIH Guidelines: III-D-4-a

Summary: In this protocol, the PI will study the neural mechanisms underlying the regulation of anxiety and development of anxiety disorders. AAV constructs will be used to express genes related to anxiety and these constructs will be delivered to transgenic mice by stereotaxic injection. Mice will be monitored using various imaging, behavioral and biochemical assessments.
Committee Recommendation: The committee has determined that some information in this protocol will be determined during the review of your IACUC protocol at the IACUC's December meeting. Additional modifications, if needed, will be sent after the IACUC review is completed.
Training: All training is completed and up to date.
Motion: Table
Vote Counts: 10-0-0

2) **IBC#:** 25-10-024-BL2
PI: Nonnenmann, Matthew
Title: Environmental sampling for bacteria and fungi for quantification and identification.
Biohazardous Agents: Environmental, multiple bacteria, environmental, multiple fungi
Applicable NIH Guidelines: Exempt
Summary: In this protocol environmental samples for fungal and bacterial agents sampling will be collected. Samples will be collected by impaction on agar plates or some in liquid medium. Samples will be cultured and types of organisms identified.
Committee Recommendation: Schedule a laboratory inspection. Work with UNMC Biosafety to determine what potential 'high consequence' pathogens could be encountered and to develop reference materials to aid in identifying those pathogens by growth characteristics/morphology. Add a statement about potential targeting of yeasts. Work with occupational health to identify animal exposure needs. Add a statement to indicate that animal welfare, biosafety, and biosecurity policies and procedures, as outlined by the farms/animal housing locations will be followed. Add a statement that farm/animal housing specific personnel will not be performing sampling or handling biohazardous materials.
Training: Three personnel need to complete training before approval.
Motion: Conditionally Approved
Vote Counts: 10-0-0

F. IBC Change in Protocol

3) **IBC#:** 08-07-017-ABL2
PI: Ahmad, Iqbal
Title: Phenotype screening of stem cell using lentiviral promoter-reporter and shRNA expression constructs.
Biohazardous Agents: AAV, human cell lines, human cells/tissues, Lentiviral vector, murine cells, murine primary cells, rabies viral vector, replication deficient
Applicable NIH Guidelines: III-D-1-a, III-D-3-a, III-D-4-b
Summary: Change request to add the use of replication defective rabies viral vector to study synaptic transfer and neuronal viability.
Committee Recommendation: Update Section I.7 if working with cells mentioned in the IACUC protocols. Add a sentence indicating that no live rabies virus will be used or generated. Select the applicable agents for the human cells, murine cells, and AAV and complete the questions that populate. Please indicate whether the viral vector is obtained ready to use or if the vector will be generated in the lab. Update the reference number or

include a link to the rabies viral vector product. Work with occupational health to determine an exposure plan and update information in section II.4 accordingly.
Training: One personnel needs to complete training before approval.
Motion: Conditionally Approved
Vote Counts: 10-0-0

4) **IBC#:** 25-07-017-ABL2
PI: Liu, Zhenguo
Title: Studies on Inflammation and Diseases
Biohazardous Agents: Escherichia *coli* K-12, *Helicobacter pylori,* Human cell line/cells/tissues, murine cell line, murine primary cells, lentiviral vector, miRNA micro, plasmid, siRNA
Applicable NIH Guidelines: III-D-1-a, III-D-3-a
Summary: Change request for adding BALB/c mice and using coxsackievirus B3 to inject via intraperitoneal injection to induce viral myocarditis.
Committee Recommendation: In section III.9a, change the response to "for the duration of life" in regards to animals being contained at this biosafety level. Update IBC according to the IACUC protocol that is linked. Schedule a time to finalize the BSL2 inspection.
Training: All training is completed and up to date.
Motion: Conditionally Approved
Vote Counts: 10-0-0

5) **IBC#:** 18-01-001-ABL2
PI: Xie, Jingwei
Title: Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing for Tissue Regeneration
Biohazardous Agents: *Acinetobacter baumannii, Bacillus subtilis, Escherichia coli* K-12, Human cell line/cells/tissues, *Klebsiella pneumoniae,* Murine cell line, *Pseudomonas aeruginosa, Staphylococcus aureus,* methicillin-resistant, Lentiviral vector, Plasmid
Applicable NIH Guidelines: III-D-4-a
Committee Recommendation: The reviewers indicated that the protocol was lengthy and difficult to follow. They noted that there appears to be a few separate/distinct projects and felt those projects should be captured on separate IBC protocols. A new IBC application form will be released soon, at that time you will be asked to submit two new protocols (one for bacterial work, one for bone regeneration/other).
Training: One personnel needs to complete training.
Motion: Conditionally Approved
Vote Counts: 10-0-0

G. IBC Continuing Review Active Research

6) **IBC#:** 24-11-036-BL2
PI: Evans, Jared
Title: Molecular characterization of influenza virus
Biohazardous Agents: Human cell line/cells/tissues, influenza viruses (not highly pathogenic), vesicular stomatitis virus
Applicable NIH Guidelines: III-D-1-a, III-D-3-a
Summary: This is a continuing review application from Jared Evans. No changes are requested. This project aims to develop platforms to rapidly characterize influenza virus

evolutionary trajectories. The investigators state that they will only produce known strains that do not possess any gain of function characteristics for transmissibility or pathogenicity.
Committee Recommendation: None
Training: Training is completed and up to date.
Motion: Approved
Vote Counts: 10-0-0

7) **IBC#:** 24-11-041-BL2
PI: Evans, Jared
Title: Characterizing pathogen replication under countermeasure exposure
Biohazardous Agents: Herpes simplex types 1 and 2, Human cell line/cells/tissues, Human Immunodeficiency virus types 1 and 2 (not concentrated), Influenza viruses (not highly pathogenic), respiratory syncytial virus, retroviral vector
Applicable NIH Guidelines: III-D-1-a
Summary: This protocol will be used to develop tests and protocols for medical countermeasures against viral pathogens. Hamster, canine, monkey and human cells will be infected with HSV, HIV or influenza viruses and then treated with countermeasures.
Committee Recommendation: none
Training: Training is completed and up to date.
Motion: Approve
Vote Counts: 10-0-0

8) **IBC:** 24-11-039-ABL2
PI: Lewis, Robert
Title: Cre-mediated recombination in neuroendocrine cells
Biohazardous Agents: Adenoviral vectors
Applicable NIH Guidelines: II-D-4-a; III-D-1-a
Summary: This protocol will use genetically modified mice to determine the role of KSR1 and KSR2 in the development of small cell lung cancer. An adenoviral vector-Cre recombinase system will be used to express genes in mice**.**
Committee Recommendation: Contact the IBC to schedule the BSL2/ABSL2 laboratory inspection. Reach out to comparative medicine for OSP and training before starting work with adenovirus in animals.
Training: Training is completed and up to date.
Motion: Conditionally Approved
Vote Counts: 10-0-0

9) **IBC#:** 22-09-027-BL2
PI: D'Angelo, Christopher
Title: Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma
Biohazardous Agents: Human cell line/cells/tissues, lentiviral vector
Applicable NIH Guidelines: III-C-1
Summary: This protocol describes the use of out-of-specification Cilta-cel, an autologous B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy. T-cells are collected from the patient during apheresis and shipped to Janssen for manufacturing into the final CAR-T cell product using a lentiviral vector system.
Committee Recommendation: Asked to make small changes to Section I, such as updating lab rooms. Provide a description of where the processing of samples occurs. Attach the mentioned "quick reference chart". Add a sentence about centrifugation and the use of aerosol control methods.

Training: All training is completed and up-to-date.
Motion: Tabled
Vote Counts: 10-0-0

10) **IBC#:** 24-11-037-BL2
PI: Fauver, Joseph
Title: Determining Population Structure of Tick Vectors in Nebraska
Biohazardous Agents: *Borrelia burgdorferi*, *Ixodes scapularis*
Applicable NIH Guidelines: exempt
Summary: There are no changes requested. The overall goal of this project is to i) determine the population structure of these two population foci identified in Nebraska ii) estimate the relatedness of these foci to other I. scapularis populations in surrounding states using a population genomic approach.
Committee Recommendation: none
Training: All training is completed and up-to-date
Motion: Approved
Vote Counts: 10-0-0

11) **IBC#:** 22-08-026-BL2
PI: Fauver, Joseph
Title: Molecular Characterization of Parasitic Nematodes
Biohazardous Agents: *Anasakis simplex, Ancyclostoma caninum, Anyclostoma ceylanicum, Ascaris sp., Brugia malayi, Dirofilaria immitus, Necator americanus, Toxocara canis*
Applicable NIH Guidelines: exempt
Summary: The goal of this project is to generate long-read genomic DNA sequencing data for several species of parasitic nematodes of medical and veterinary importance that span the breadth of nematode diversity.
Committee Recommendation: none
Training: All training is completed and up-to-date.
Motion: Approved
Vote Counts: 10-0-0

12) **IBC#:** 24-10-033-BL2
PI: Sharma, Bhavina
Title: KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs.
Biohazardous Agents: Herpes virus vector, Human cell line/cells/tissues
Applicable NIH Guidelines: III-C-1
Summary: Replication-defective, non-integrating HSV-1 based vector for delivery of full-length IL-12 and L-2 to patients with malignant solid lung tumors.
Committee Recommendation: In Section V.1 – change answer to 'none of the above.'
Training: All training is completed and up-to-date.
Motion: Conditionally Approved
Vote Counts: 10-0-0

13) **IBC#:** 21-01-002-ABL2
PI: Pathania, Anup
Title: Ethanol Suppresses HBV peptide MHC class I complex presentation on hepatocytes.
Biohazardous Agents: Hepatitis B
Applicable NIH Guidelines: exempt

Summary: This protocol describes studies to investigate the potentiation mechanisms of alcohol use and hepatitis B infection. The study uses transgenic mice that produce HBV. Mice are not infected in-house with HBV.
Committee Recommendation: Update personnel involved in the protocol. Add a sentence to Section II.1 to identify the location for flow cytometry. Add a brief description of the neutralization/inactivation that occurs prior to this procedure, include concentration and contact time.
Training: Two personnel need to complete their training before full approval.
Motion: Conditionally Approved.
Vote Counts: 10-0-0

14) **IBC#:** 20-11-046-ABL2
PI: Hollingsworth, Michael
Title: Use of Lentiviral Vectors to investigate the role of MUC1, Notch, PTP1B, PTP-PEST, PTPN9, Annexin A7, ERBB receptors family, transglutaminase 2 and HLA-A in Pancreatic Cancers.
Biohazardous Agents: Human cell line/cells/tissues, CRISPR-Cas9, Lentiviral Vector, Plasmid, shRNA short hairpin
Applicable NIH Guidelines: III-D-1-a, III-D-3-a
Summary: Continuing Review including a change request. Research involves lentiviral vector modification of human and murine cells to investigate the roles of various genes in tumor progression/metastatic potential. Change is to add additional genes of interest, PTP-PEST, PTPN9, PTPN12, that dephosphorylate ERBB receptors.
Committee Recommendation: Clarify if PTPN12 and PTPN9 are both being used, or just one. Update Section II with information about sources of new materials being used. Update Section II.2.C with information about genes and gene products.
Training: All training is completed and up-to-date.
Motion: Conditionally Approved
Vote Counts: 10-0-0

There being no further business, Dr. McMillan adjourned the meeting at 3:42pm

Respectfully Submitted,

[redacted]

JoEllyn McMillan, PhD
Chair, IBC
JM

ADDENDUM
November 13, 2025
IBC REVIEW LETTER/EMAIL TO INVESTIGATORS

IBC #	Date of Letter/Email
25-10-023-Pending	11/14/2025
25-10-024-Pending	11/14/2025
08-07-017-ABL2	11/14/2025
25-07-017-ABL2	11/14/2025
18-01-001-ABL2	11/14/2025
24-11-036-BL2	11/14/2025
24-11-041-BL2	11/14/2025
24-11-039-ABL2	11/14/2025
22-09-027-BL2	11/14/2025
24-11-037-BL2	11/14/2025
22-08-026-BL2	11/14/2025
24-10-033-BL2	11/14/2025
21-01-002-ABL2	11/14/2025
20-11-046-ABL2	11/14/2025